Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Post-ASCO 2024 Lung Cancer Highlights

Interactive webinar featuring presentations & discussions on selected abstracts from ASCO 2024
Chair: Professor Sanjay Popat | Moderator: Dr Melissa Johnson
19 June | 10:00–11:30 CDT/ 16:00–17:30 BST/ 17:00–18:30 CEST

Draft Agenda

(subject to change)

Timings are in CDT

10:00–10:10 | Session 1: Latest in consolidative therapy and palliative care
  • NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC) – #8506: Puneeth Iyengar
  • Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer – #LBA3: Joseph Greer
10:10–10:25 | Session 2: Advances in resectable lung cancer
  • Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816 – #LBA8010: Nicolas Girard
  • Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFRmutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC) – #8005: Tom John
10:25–10:45 | Panel discussion
10:45–10:55 | Session 3: Updates in EGFR mutated lung cancer EGFR-targeted therapies
  • Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study – #LBA4: Terufumi Kato
  • Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial – #LBA8505: Natasha Leighl
10:55–11:10 | Session 4: Advances with targeted therapies
  • Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study – #LBA8503: Benjamin Solomon
  • Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study – #LBA8500: Luis Paz-Ares
  • BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)—Results from the ETOP 13-18 trial – #LBA8002: Sanjay Popat
11:10–11:30 | Panel discussion
11:30 | End of webinar

This webinar is for HCPs and allied health professionals only. Please apply for registration and we’ll confirm your application once received.